News
December 28, 2011
Immunomedics And UCB Announce Restructuring Of EPRATUZUMAB License Agreement
December 14, 2011
Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing
December 13, 2011
Immunomedics Announces Results From Two Clinical Trials at Hematology Conference
December 12, 2011
Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas
December 12, 2011
December 09, 2011
Immunomedics Creates Targeted Therapeutics for Solid Cancers
December 07, 2011
Immunomedics Announces Outcome of 2011 Annual Meeting of Stockholders
December 06, 2011
Immunomedics Presentations at the Oppenheimer 22nd Annual Healthcare Conference
November 16, 2011
Immunomedics Presentations at 2011 annual meeting of American Society of Hematology (ASH)
November 15, 2011
Immunomedics Awarded Additional U.S. Patent For Anti-CD20 Treatment Of Autoimmune Diseases
November 11, 2011
November 8, 2011
Epratuzumab Phase IIb Data Demonstrated Sensitivity of BICLA, A Novel BILAG-Based Composite Endpoint
November 7, 2011
Immunomedics To Participate In Upcoming Conferences
November 4, 2011
Immunomedics Announces First Quarter Fiscal 2012 Results and Clinicl Program Developments
November 2, 2011
Immunomedics Announces FDA Allows Resumption Of Clivatuzumab Tetraxetan Clinical
October 11, 2011
Immunomedics Awarded U.S. Patent For Cytokine-Antibody
September 22, 2011
Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical Trial
September 12, 2011
Immunomedics to Present at 2011 UBS Global Life Sciences Conference
September 2, 2011
Immunomedics to Webscast Presentation at Stifel Nicolaus 2011 Healthcare Conference
August 24, 2011
August 9, 2011
Immunomedics to present at Wedbush Securities 2011 Life Sciences Management Access Conference
July 19, 2011
Immunomedics awarded additional patent for PEGylation Method
June 27, 2011
Immunomedics receives third milestone payment from Nycomed
June 16, 2011
Immunomedics to present at 2011 Wells Fargo Securities Healthcare Conference
June 7, 2011
June 7, 2011
June 6, 2011
June 3, 2011
Immunomedics to present at Jefferies 2011 Global Healthcare Conference
June 2, 2011
Immunomedics announces presentations at the 16th Congress of the European Hematology Association
May 31, 2011
May 10, 2011
Immunomedics announces third quarter fiscal 2011 results and clinical program developments
May 3, 2011
Immunomedics to present at Bank of America Merrill Lynch 2011 Health Care Conference
May 2, 2011
April 6, 2011
April 6, 2011
Immunomedics announces preclinical results of TF2 for pretargeted imaging of colon cancer
April 5, 2011
Immunomedics presents new DNL-derived antibodies for mantle cell lymphoma at AARC annual meeting
April 5, 2011
Immunomedics reports progress on development of antibody-SN-38 conjugates at cancer meeting
April 4, 2011
Immunomedics develops new DNL-derived antibody-interferon conjugate for blood cancer treatment
March 28, 2011
March 24, 2011
March 9, 2011
Immunomedics awarded two additional US patents for dock-and-lock technology
February 25, 2011
Immunomedics announces presentations at upcoming healthcare conferences
February 4, 2011
Immunomedics announces second quarter fiscal 2011 results and clinical program developments
January 24, 2011
January 21, 2011
Immunomedics reports targeted therapy for advanced pancreatic cancer improves survival
